Moderna
was climbing Monday immediately after an analyst at Jefferies upgraded the stock citing self esteem in the vaccine maker’s growth prospects that are not linked to the Covid-19 vaccine.
Jefferies analyst Michael Yee upgraded shares of Moderna (ticker: MRNA) to Buy from Keep and increased his 12-thirty day period selling price target on the inventory to $275 from $170. For Moderna, Yee stated he sees a “significant new pipeline story and catalysts ahead.”
Moderna
was climbing Monday immediately after an analyst at Jefferies upgraded the stock citing self esteem in the vaccine maker’s growth prospects that are not linked to the Covid-19 vaccine.
Jefferies analyst Michael Yee upgraded shares of Moderna (ticker: MRNA) to Buy from Keep and increased his 12-thirty day period selling price target on the inventory to $275 from $170. For Moderna, Yee stated he sees a “significant new pipeline story and catalysts ahead.”
